View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Philip Ekengren

Attendo AB: 1 director

A director at Attendo AB maiden bought 60,000 shares at 60.500SEK and the significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Stefan Knutsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Stefan Knutsson

Team Olivia integrated as planned

Adj. EPS 8% ahead of consensus. Positive long-term revisions driven by FX. Still on track for '26 adj. EPS target.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Stefan Knutsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Stefan Knutsson

A new chapter begins with Team Olivia

Q2 due 19 July, focus on integration. FX and Finland behind est. revisions, '24e adj EBITA -3%. We are still on the cautious side : HOLD.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Stefan Knutsson

New financial targets in focus

Aims for adj. EPS of at least SEK 5.50 in '26. Driven by 10% EBITA CAGR and buybacks. We trim our long-term assumptions.

Stefan Knutsson
  • Stefan Knutsson

Attendo - Solid occupancy improvements in Scandinavia

Q3 slightly better than expected Finland still on track for a turnaround in 2023 Focus is on occupancy amid high inflation

Stefan Knutsson
  • Stefan Knutsson

Attendo - Short-term beat, no news about FI negotiations

5.7% EBITA beat vs ABGSCe, 10.1% vs cons ‘22e to come up ~4%, FI negotiations paused Share to outperform by low to mid-single digits

Erik Cassel ... (+3)
  • Erik Cassel
  • Jakob Lembke
  • Stefan Knutsson

Attendo - Staffing law delayed, positive for 2023e costs

Q3 report due on 26 October Final nursing staff requirement increases postponed Minor estimate changes

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

Attendo - Finland profitability truly back on the table

Weaker-than-expected Q2 on sick leave and inflation On track for 30% price increase in Finland from April ’23 ’22/’23e -37%/0%, lease-adj. FCF yield ‘23e 16%

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch